Wegovy maker Novo Nordisk sues rival over 'knock-off' weight-loss drugs

Novo Nordisk filed a US suit seeking to ban Hims & Hers' compounded weight-loss pills and injections, alleging patent infringement and safety risks; Hims & Hers paused sales of a newly launched pill and its shares fell about 16% on Monday while Novo Nordisk's stock ticked up. Novo cited recent FDA warnings about compounded GLP-1 drugs and potential impurities, framing the action as both a public‑health and IP defense; the dispute could constrain compounding competitors, affect Hims & Hers' growth prospects, and reinforce pricing/protection for branded products amid Novo Nordisk's broader pressures from patent expiries and recent profit guidance concerns.

Analysis

Market structure: Novo Nordisk (NVO) and large branded GLP‑1 makers (e.g., Eli Lilly LLY) are net beneficiaries if courts/FDA curb compounding — expect improved pricing power and 1–3ppt gross margin tailwind on GLP‑1 lines over 3–12 months as lower‑priced knock‑offs are restricted. Short‑term losers include telehealth/compounding players (HIMS) and independent compounding pharmacies; HIMS already fell ~16% intraday, implying elevated equity and options volatility for weeks. Cross‑asset: expect HIMS implied volatility to remain elevated (tradeable), modest positive sentiment to NVO equities and corporate credit, negligible commodity/FX moves aside from modest DKK tailwind to US revenue translation.

Risk assessment: key tail risks — unfavorable court ruling or FDA permitting broader compounding (low probability, high impact) could erode branded pricing by >10% of GLP‑1 revenue over 12–24 months; regulatory/advertising scrutiny of NVO can trigger 5–10% headline volatility in days. Immediate window (days): share moves around filings and press; short term (weeks–months): injunctions, FDA guidance; long term (quarters–years): patent cliffs and insurer formulary shifts. Hidden dependency: insurer reimbursement and prescriber adoption can amplify or mute outcomes; anti‑trust/consumer backlash is a nontrivial second‑order risk.

trade implications: tactical trades — short HIMS (HIMS) equity or buy 1–3 month ATM puts sized to 1–2% NAV given IV spike; establish 1–2% long NVO with a 3–6 month horizon or a 3–6 month call spread 5–10% OTM to limit capital. Pair trade: long NVO / short HIMS 1:1 notional to isolate GLP‑1 enforcement upside. Rotate sector overweight to large-cap branded pharma (NVO, LLY) and underweight telehealth/compounding names.

contrarian angles: consensus assumes swift NVO legal victory; history shows compounding often persists via workarounds — if FDA/legislature delays enforcement >90 days, compounded supply could permanently capture 5–15% share and cap price gains. A hard enforcement stance could provoke policy pushback or faster biosimilar approvals; monitor court injunction timelines (30–90 days) and FDA compounding guidance (next 30–60 days) as binary catalysts.

Key Decisions for Investors

• Initiate a 1.5% NAV long position in Novo Nordisk (NVO) with a 3–6 month horizon; hedge downside with a funded 3–6 month call spread (buy 5% OTM, sell 15% OTM) to cap cost and capture enforcement upside; reduce/add if NVO moves >5% on FDA ad ruling within 30 days.
• Establish a 1% NAV short in Hims & Hers (HIMS) equity or buy 1–3 month ATM puts (size 1% NAV) given elevated IV and legal exposure; set stop‑loss at +20% on option premium or close equity short if HIMS rebounds >25% intra‑week absent new info.
• Execute a pair trade: long NVO vs short HIMS notional 1:1 sized to 2% NAV to isolate patent enforcement outcome; rebalance if court grants/denies preliminary injunction within 30–90 days.
• Overweight large‑cap branded pharma (add 1–3% NAV to LLY, NVO) and underweight telehealth/compounding operators (trim HIMS exposure by at least 50%); reassess after FDA publishes compounding guidance (monitor window: 30–60 days).
• Monitor two binary catalysts before scaling: (A) court filings/injunction decision on HIMS within 30–90 days and (B) FDA compounding guidance/advertising resolution for NVO within 30 days; increase exposure only if both tilt toward enforcement (e.g., injunction granted AND restrictive FDA guidance).